In short, we need treatments that reverse the hyperinsulinemia resulting from impairments in insulin signaling or glucose metabolism, as hyperinsulinemia can hyperactivate uninhibited or partially inhibited insulin‐signaling pathways and provoke adverse effects. The gene discussed is INS; the disease is hyperinsulinism.